Comecer IRIS Radiopharmaceutical Multidose Injector can now inject therapeutic radiopharmaceuticals based on ¹⁷⁷Lu for Radionuclide Therapy

A variety of radiopharmaceuticals have been introduced for the internal therapy of malignant and inflammatory lesions in nuclear medicine. In order to destroy the diseased tissues radionuclides with high linear energy transfer (LET) such as beta, alpha, Auger or low energy conversion electron emitters are needed. The range of beta particles is in mm’s so they are effective for large tumors. The range of alpha particles is short, only a few cell diameters. Thus, they are effective in treating circulating malignant cells and micrometastases.
The range of Auger and conversion electrons is <0.1 microm. They are very effective in cell killing when they are carried across cell membrane into the nucleus to damage DNA. Appropriate ions, molecules and particles are labelled with such radionuclides and used as radiopharmaceuticals in many different applications.

With the latest IRIS software release and the introduction of the MULTISTROKE, it’s finally possible to use our IRIS certified medical device for the injection of therapeutic radiopharmaceuticals. The most requested ones, nowadays, are radiopharmaceuticals labeled with ¹⁷⁷Lu: (¹⁷⁷Lu-DOTATATE, LUTATHERA^®, and ¹⁷⁷Lu-PSMA-617, Pluvicto^TM). It's a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut. Pluvicto^TM is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
IRIS automatically injects calibrated doses to patients, starting from a multi-dose/mono-dose solution of radiopharmaceuticals.
The new software update can even be performed remotely and for therapeutic radiopharmaceuticals the latest software version is highly recommended.

Read the entire article by submitting the form